CoLucid Pharmaceuticals, Inc.
CLCD
CLCD was delisted on the 28th of February, 2017.
20 hedge funds and large institutions have $46.3M invested in CoLucid Pharmaceuticals, Inc. in 2016 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 8 reducing their positions, and 5 closing their positions.
36% more capital invested
Capital invested by funds: $34.1M → $46.3M (+$12.2M)
0.92% more ownership
Funds ownership: 36% → 36.92% (+0.92%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9% less funds holding
Funds holding: 22 → 20 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
75% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.49M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$455K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.04K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$897K |
| 2 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
-$186K |
| 3 |
Morgan Stanley
New York
|
-$62.5K |
| 4 |
Millennium Management
New York
|
-$62K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$8K |
CLCD Hedge Fund Activity: Q2 2016 in Review
20 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in CoLucid Pharmaceuticals, Inc. (CLCD) for Q2 2016, worth a combined $46.3M — up 36% from $34.1M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CLCD and 3 opened new positions — a net loss of 2 holders — while 8 trimmed existing stakes and 2 added.
The largest buyer was Sphera Funds Management, adding an estimated $1.49M. The largest seller was UBS O'Connor, cutting an estimated $897K.
- 20 institutional investors held CoLucid Pharmaceuticals, Inc. (CLCD) as of Q2 2016, down from 22 in Q1 2016.
- Funds reported $46.3M of CoLucid Pharmaceuticals, Inc. stock for Q2 2016, up 36% quarter-over-quarter.
- 3 funds opened new CoLucid Pharmaceuticals, Inc. positions in Q2 2016 and 5 closed out, a net change of -2 holders.
- The largest CoLucid Pharmaceuticals, Inc. buyer in Q2 2016 was Sphera Funds Management, an estimated $1.49M added.
- The largest CoLucid Pharmaceuticals, Inc. seller in Q2 2016 was UBS O'Connor, an estimated $897K sold.
Based on aggregated 13F filings for Q2 2016.